Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2025)

BridgeBio Pharma's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 23.49% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, down 23.49%, while the annual FY2025 figure was $13.1 million, 23.49% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $13.1 million at BridgeBio Pharma, roughly flat from $13.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $19.9 million in Q1 2024 and bottomed at $3.7 million in Q4 2023.
  • The 3-year median for Non-Current Deffered Revenue is $17.0 million (2024), against an average of $15.0 million.
  • The largest annual shift saw Non-Current Deffered Revenue surged 358.68% in 2024 before it fell 29.51% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $3.7 million in 2023, then soared by 358.68% to $17.1 million in 2024, then decreased by 23.49% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Non-Current Deffered Revenue are $13.1 million (Q4 2025), $13.1 million (Q3 2025), and $14.7 million (Q2 2025).